Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Elcometrine/estradiol - Population Council/Therapeutics MD

Next Previous
Drug Profile

Elcometrine/estradiol - Population Council/Therapeutics MD

Alternative Names: Annovera; Elcometrine/estradiol ATD™ gel; Estradiol/elcometrine transdermal gel - Antares Pharma/Population Council; Estradiol/elcometrine vaginal ring; NES-E2 CVR; NES/E2; NES/EE/CVR; Nestorone®/estradiol; NestraGel; Ringza; Segesterone acetate and ethinyl estradiol vaginal system; Segesterone acetate/ethinyl estradiol vaginal ring; Segesterone acetate/ethinyl estradiol vaginal system

Latest Information Update: 05 Dec 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Antares Pharma; Population Council (USA)
  • Developer Antares Pharma; Duchesnay Inc; Population Council (USA); TherapeuticsMD
  • Class Estradiol congeners; Estrenes; Hormonal contraceptives; Small molecules
  • Mechanism of Action Estrogen receptor agonists; Progesterone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Pregnancy

Most Recent Events

  • 30 Nov 2023 Preregistration for Pregnancy (Prevention) in Canada (Vaginal)
  • 03 Jan 2023 TherapeuticsMD completes transaction to license Elcometrine/estradiol to Mayne Pharma
  • 27 Dec 2022 Phase-I development is ongoing in Pregnancy (Prevenion) in Canada (Vaginal) (NCT04290390)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top